Reparixin

236,00 €

Zzgl. MwSt.

ArtNr	HY-15251-50mg
Hersteller	MedChem Express
CAS-Nr.	266359-83-5
Menge	50 mg
Kategorie	Neuroscience Neuroinflammation Metabolism Diabetes Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	99.98
Formula	C14H21NO3S
Citations	Ann Rheum Dis. 2016 Apr;75(4):730-8. Biochim Biophys Acta. 2017 Jan;1863(1):220-230. BMC Med. 2022 Feb 8;20(1):55. Cancer Cell Int. 2021 Jul 3;21(1):337. Cancer Cell. 2023 Apr 10;41(4):693-710.e8. Cancers (Basel). 2023 Sep 4;15(17):4422. Cell Biosci. 2019 Jan 3;9:4. Cell Commun Signal. 2023 Mar 13;21(1):59. Cell Death Dis. 2017 Jul 13;8(7):e2932. Cells. 2022 Jun 21;11(13):1986. Cells. 2022, 11(15), 2402. EBioMedicine. 2019 May;43:487-500. FACETS. 2020 Jul. Front Immunol. 17 October 2022. Front Immunol. 2021 May 7;12:667177. Front Immunol. 2018 Sep 12;9:2058. Gene. 2018 Nov 30;677:149-162. J Allergy Clin Immunol. 2018 Jun;141(6):2286-2289.e5. J Cell Mol Med. 2020 Jan;24(2):1588-1598. J Cell Mol Med. 2020 Nov;24(21):12608-12618. J Gastroenterol Hepatol. 2018 Feb;33(2):431-442. J Immunol. 2018 Jul 15;201(2):814-820. J Mol Cell Biol. 2023 Apr 18;mjad025. J Mol Med (Berl). 2019 Jan;97(1):25-35. Johns Hopkins University. Department of Chemical and Biomolecular Engineering. 2016 Dec. Karolinska Institutet. Dept of Physiology and Pharmacology. 2022 Feb. Mol Immunol. 2018 Aug 7;101:440-449. Mol Ther. 2022 Jul 14;S1525-0016(22)00429-4. Nat Commun. 2017 May 26;8:15584. Oncogenesis. 2016 Jun 13;5(6):e234. Oncotarget. 2017 Jul 21;8(36):60210-60222. Oncotarget. 2018 Aug 24;9(66):32556-32569. Patent. US20220251222A1. Research Square Preprint. 2021 Mar. Research Square Preprint. 2022 Jan. Sci Adv. 2019 May 8;5(5):eaav7384. Sci Rep. 2017 Nov 6;7(1):14510. Stem Cells. 2015 Dec;33(12):3558-68. University of Michigan. 2018 Oct. Vet Immunol Immunopathol. 2016 Dec;182:52-58. Xenotransplantation. 2018 Mar;25(2):e12385. Ann Rheum Dis. 2016 Apr;75(4):721-9. Biomed Res Int. 2020 Aug 5;2020:4670604. bioRxiv. 2020 Sep 12;2020.08.25.265561. Neurobiol Dis. 29 October 2021, 105538. Patent. US20170105971A1. Patent. US20170181987A1. [1]Moriconi A, et al. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J Med Chem. 2007 Aug 23;50(17):3984-4002. [2]Bertini R, et al. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2non-competitive allosteric inhibitor. Br J Pharmacol. 2012 Jan;165(2):436-54. [3]Kim HY, et al. Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats. Biol Pharm Bull. 2011;34(1):120-7. [4]Sousa LF, et al. Blockade of CXCR1/2 chemokine receptors protects against brain damage in ischemic stroke in mice. Clinics (Sao Paulo). 2013;68(3):391-4. [5]Bertini R, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6. [6]Krishnamurthy A, et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis. 2016 Apr;75(4):721-9. [7]Crespo J, et al. Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. J Immunol. 2018 Jul 15;201(2):814-820.
Smiles	CS(=O)(NC([C@@H](C1=CC=C(CC(C)C)C=C1)C)=O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Repertaxin; DF 1681Y
Lieferbar
Product Description	Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors CXCR1 and CXCR2 activation with IC50s of 1 and 100 nM, respectively.
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	COVID-19-immunoregulation
Molecular Weight	283.39
Clinical Information	Phase 3
Solubility	DMSO : ≥ 100 mg/mL\|H2O : 1 mg/mL (ultrasonic; warming; heat to 80°C)
Isoform	CXCR1; CXCR2
Pathway	GPCR/G Protein; Immunology/Inflammation
Manufacturers Product type	Reference compound

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-15251-50mg-safety-datasheet.pdf